Welcome to Kidney Cancer Care

Welcome to the McMaster University - St. Joseph’s Healthcare Kidney Cancer Centre of Excellence (KCCE) website. This is a patient-oriented portal providing information and links regarding the cutting edge management of kidney cancer. Here you will find up-to-date information about kidney cancer and its treatment, recent advances in management, current clinical research information, and links to our basic science research program. We hope you find this website informative and useful and we welcome your feedback.

Anil Kapoor, MD, FRCSC
Director
McMaster – SJH Kidney Cancer Centre of Excellence (KCCE)

Get the Flash Player to see this player.

 
What’s new in Kidney Cancer Care
April 25th, 2016
On April 25, 2016, the U. S. Food and Drug Administration approved cabozantinib (CABOMETYX, Exelixis, Inc.) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy. 
March 24th, 2016
In a phase II trial of patients with metastatic clear cell renal cell carcinoma, everolimus was associated with better progression-free survival than apitolisib.
January 19th, 2016
Cabozantinib improved progression-free survival in patients with advanced renal cell carcinoma compared with everolimus. These findings of the randomized, phase 3 METEOR trial were reported at the 2016 Genitourinary Cancer Symposium.